Preclinical biologic assessment of proton beam relative biologic effectiveness at Proton Therapy Center Houston.
The clinical use of protons for the treatment of cancer is one of the most technologically advanced forms of therapy. The newly commissioned M.D. Anderson Cancer Center, Proton Therapy Center Houston is one of the newest facilities offering a complete range of advanced proton therapies designed specifically to minimize treatment-related normal tissue toxicity. As an integral part of the clinical commissioning of this proton beam, we performed an in vivo assessment of the relative biologic effectiveness of the 250-MeV protons relative to standard cobalt(60) using the jejunal crypt microcolony assay in mice. Our data are consistent with a generic relative biologic effectiveness of 1.1, and this relative biologic effectiveness is in agreement with that used to describe most other clinical proton therapy beams worldwide.
Mason
Kathryn A
KA
Department of Experimental Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Gillin
Michael T
MT
Mohan
Radhe
R
Cox
James D
JD
D000818:Animals; D002470:Cell Survival / Q000528:radiation effects; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006782:Hospitals, Special; D007583:Jejunum / Q000166:cytology / Q000528:radiation effects*; D051379:Mice; D008809:Mice, Inbred C3H; D061766:Proton Therapy; D012062:Relative Biological Effectiveness; D013781:Texas
D003037:Cobalt Radioisotopes